BRUNO DALLAPICCOLA
– CONGRESS PRESIDENT –
Scientific Director, Bambino Gesù Children’s Hospital, Rome, Italy
BRUNO DALLAPICCOLA
– CONGRESS PRESIDENT –
Scientific Director, Bambino Gesù Children’s Hospital, Rome, Italy
ALBERTO EUGENIO TOZZI
– CHAIR OF SCIENTIFIC COMMITTEE –
Chief Innovation Officer and Head of the Multifactorial and Complex Disease Research Area, Bambino Gesù Children’s Hospital, Rome, Italy
Roberto Ascione
CEO – Healthware International – Salerno – Italy
Sherry Farrugia
Chief Operating & Strategy Officer – Pediatric Technology Center – Georgia Institute of Technology, Atlanta GA (USA)
Franco Locatelli
Head of Department of Haematology, Oncology and Transfusion Medicine – Children’s Hospital Bambino Gesù – Rome – Italy
Lorenzo Moretta
Head Dept. of Immunology and Dept. of Laboratories and Diagnostic Immunology – Children’s Hospital Bambino Gesù – Rome – Italy
Laura Palazzani
Professor of Philosophy of Right – LUMSA University – Rome – Italy
Massimiliano Raponi
Medical Director – Children’s Hospital Bambino Gesù – Rome – Italy
Paolo Rossi
Head of Academic Department of Pediatrics – Bambino Gesù Children’s Hospital – Rome – Italy
Marco Tartaglia
Head of Molecular Genetics and Functional Genomics Research Unit and Genetics and Rare Disease Research Division – Children’s Hospital Bambino Gesù – Rome – Italy
Alberto Villani
Italian Society of Pediatrics, President – Rome, Italy
Dawn Wolff
Senior Director of Strategic and Initiative Development – Children’s Mercy Kansas City, Kansas City MO (USA)
Anna Zanin
PICU consultant at Azienda Sanitaria ULSS 6 (Health Authority) – Vicenza – Italy
Sepsis in children is a complex syndrome that develops from various infections and results in 15-30% mortality in high-income countries and up to 50% or higher in low-income countries. Worldwide, this represents an annual burden of 30 million cases resulting in 8 million deaths. Not surprisingly, there is a significantly higher burden in low-income countries with children there being 18 times more likely to die before the age of 5 years compared to high-income countries. Factors such as commercial air travel, climate change, and unchecked population growth have contributed to the growing burden of infectious diseases and ensuing sepsis. Improving public awareness of sepsis; increasing access to essential medicines and vaccines; improving use of evidence-based treatment guidelines; raising awareness of antimicrobial resistance, encouraging antibiotic stewardship; and, developing resilient health systems that can cope with health crises are all important challenges. Advocacy in these areas can assist nations in reaching the United Nations Sustainable Development Goals (UN SDGs) of low rates of neonatal and under-5 mortality.
On May 26, 2017, the World Health Assembly, the decision-making body of the World Health Organization, adopted a resolution proposed by the Global Sepsis Alliance to improve the prevention, diagnosis, and management of sepsis.The resolution highlights sepsis as a global threat and urges the 194 United Nations member states to take specific actions and implement appropriate measures to reduce its human and health economic burden. The resolution is a major step toward achieving the targets outlined by the Sustainable Developmental Goals for decreasing mortality in infants and children, but implementing it will require a concerted global effort.
update on number of registrants: 18/50 (sept 29th)
€ 150,00
update on number of registrants: 17/50 (sept 29th)
€ 150,00
update on number of registrants: 12/50 (sept 29th)
€ 150,00
update on number of registrants: 7/50 (sept 29th)
€ 150,00
update on number of registrants: 18/60 (sept 29th)
€ 150,00
update on number of registrants: 32/60 (sept 29th)
€ 150,00